Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: An observational cohort study

Critical Care

Volumn 15, Issue 6, 2011, Pages

  Backes, Yara ^a   van der Sluijs, Koenraad F ^a   Tuip de Boer, Anita M ^a   Jan Hofstra, Jorrit ^a   Vlaar, Alexander P J ^a   Determann, Rogier M ^a   Knape, Paul ^b   Mackie, David P ^b   Schultz, Marcus J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b RED CROSS HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; PLASMINOGEN ACTIVATOR; SOLUBLE UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR; THROMBIN ANTITHROMBIN COMPLEX; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; FOLLOW UP; HUMAN; INFLAMMATION; INTENSIVE CARE; LENGTH OF STAY; LUNG BURN; LUNG LAVAGE; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; TREATMENT DURATION; AGED; BLOOD; BURN; CASE CONTROL STUDY; CHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; NONPARAMETRIC TEST; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; BURNS; CASE-CONTROL STUDIES; COHORT STUDIES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; RESPIRATION, ARTIFICIAL; ROC CURVE; SMOKE INHALATION INJURY; STATISTICS, NONPARAMETRIC; YOUNG ADULT;

EID: 81055124185     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc10550     Document Type: Article

References (44)

1. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis Markers 2009, 27:157-172.
2. Mizukami IF, Faulkner NE, Gyetko MR, Sitrin RG, Todd RF. Enzyme-linked immunoabsorbent assay detection of a soluble form of urokinase plasminogen activator receptor in vivo. Blood 1995, 86:203-211.
3. Ostrowski SR, Ullum H, Goka BQ, Hoyer-Hansen G, Obeng-Adjei G, Pedersen BK, Akanmori BD, Kurtzhals JA. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005, 191:1331-1341. 10.1086/428854, 15776381.
4. Perch M, Kofoed P, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J. Serum levels of soluble urokinase plasminogen activator receptor are associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004, 26:207-211. 10.1111/j.0141-9838.2004.00695.x, 15491469.
5. Ostrowski SR, Piironen T, Hoyer-Hansen G, Gerstoft J, Pedersen BK, Ullum H. High plasma levels of intact and cleaved soluble urokinase receptor reflect immune activation and are independent predictors of mortality in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:23-31. 10.1097/01.qai.0000157950.02076.a6, 15851910.
6. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse I. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002, 6:686-692.
7. Garcia-Monco JC, Coleman JL, Benach JL. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. J Neuroimmunol 2002, 129:216-223. 10.1016/S0165-5728(02)00186-8, 12161038.
8. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004, 36:14-19. 10.1080/00365540310017366, 15000553.
9. Wittenhagen P, Kronborg G, Weis N, Nielsen H, Obel N, Pedersen SS, Eugen-Olsen J. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin Microbiol Infect 2004, 10:409-415. 10.1111/j.1469-0691.2004.00850.x, 15113317.
10. Koch A, Voigt S, Kruschinski C, Sanson E, Duckers H, Horn A, Yagmur E, Zimmermann H, Trautwein C, Tacke F. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011, 15:R63. 10.1186/cc10037, 3221996, 21324198.
11. Moller HJ, Moestrup SK, Weis N, Wejse C, Nielsen H, Pedersen SS, Attermann J, Nexø E, Kronborg G. Macrophage serum markers in pneumococcal bacteremia: prediction of survival by soluble CD163. Crit Care Med 2006, 34:2561-2566. 10.1097/01.CCM.0000239120.32490.AB, 16915112.
12. Huttunen R, Syrjanen J, Vuento R, Hurme M, Huhtala H, Laine J, Pessi T, Aittoniemi J. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Intern Med 2011,
13. Kofoed K, Eugen-Olsen J, Petersen J, Larsen K, Andersen O. Predicting mortality in patients with systemic inflammatory response syndrome: an evaluation of two prognostic models, two soluble receptors, and a macrophage migration inhibitory factor. Eur J Clin Microbiol Infect Dis 2008, 27:375-383. 10.1007/s10096-007-0447-5, 18197443.
14. Thompson PB, Herndon DN, Traber DL, Abston S. Effect on mortality of inhalation injury. J Trauma 1986, 26:163-165. 10.1097/00005373-198602000-00012, 3944839.
15. Suzuki M, Aikawa N, Kobayashi K, Higuchi R. Prognostic implications of inhalation injury in burn patients in Tokyo. Burns 2005, 31:331-336. 10.1016/j.burns.2004.10.016, 15774289.
16. Saffle JR, Davis B, Williams P. Recent outcomes in the treatment of burn injury in the United States: a report from the American Burn Association Patient Registry. J Burn Care Rehabil 1995, 16:219-232. 10.1097/00004630-199505000-00002, 7673300.
17. Shirani KZ, Pruitt BA, Mason AD. The influence of inhalation injury and pneumonia on burn mortality. Ann Surg 1987, 205:82-87. 10.1097/00000658-198701000-00015, 1492872, 3800465.
18. Marek K, Piotr W, Stanislaw S, Stefan G, Justyna G, Mariusz N, Andriessen A. Fibreoptic bronchoscopy in routine clinical practice in confirming the diagnosis and treatment of inhalation burns. Burns 2007, 33:554-560. 10.1016/j.burns.2006.08.030, 17376597.
19. Ambiavagar M, Chalon J, Zargham I. Tracheobronchial cytologic changes following lower airway thermal injury: a preliminary report. J Trauma 1974, 14:280-289. 10.1097/00005373-197404000-00002, 4819617.
20. Woodson LC. Diagnosis and grading of inhalation injury. J Burn Care Res 2009, 30:143-145. 10.1097/BCR.0b013e3181923b71, 19060739.
21. Hofstra JJ, Vlaar AP, Knape P, Mackie DP, Determann RM, Choi G, van der Poll T, Levi M, Schultz MJ. Pulmonary activation of coagulation and inhibition of fibrinolysis after burn injuries and inhalation trauma. J Trauma 2011, 70:1389-1397. 10.1097/TA.0b013e31820f85a7, 21460745.
22. Schultz MJ, Haitsma JJ, Zhang H, Slutsky AS. Pulmonary coagulopathy as a new target in therapeutic studies of acute lung injury or pneumonia: a review. Crit Care Med 2006, 34:871-877.
23. Millo JL, Schultz MJ, Williams C, Weverling GJ, Ringrose T, Mackinlay CI, van der Poll T, Garrard CS. Compartmentalisation of cytokines and cytokine inhibitors in ventilator-associated pneumonia. Intensive Care Med 2004, 30:68-74. 10.1007/s00134-003-2060-0, 14634726.
24. Murray JF, Matthay MA, Luce JM, Flick MR. An expanded definition of the adult respiratory distress syndrome. Am Rev Respir Dis 1988, 138:720-723.
25. Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med 2010, 11:12-17. 10.1097/PCC.0b013e3181b0653d, 2936504, 19561556.
26. Herndon DN, Traber DL, Niehaus GD, Linares HA, Traber LD. The pathophysiology of smoke inhalation injury in a sheep model. J Trauma 1984, 24:1044-1051. 10.1097/00005373-198412000-00007, 6512897.
27. Demling RH. Smoke inhalation injury. New Horiz 1993, 1:422-434.
28. Gore MA, Joshi AR, Nagarajan G, Iyer SP, Kulkarni T, Khandelwal A. Virtual bronchoscopy for diagnosis of inhalation injury in burnt patients. Burns 2004, 30:165-168. 10.1016/j.burns.2003.09.024, 15019127.
29. Fujitani S, Yu VL. Diagnosis of ventilator-associated pneumonia: focus on nonbronchoscopic techniques (nonbronchoscopic bronchoalveolar lavage, including mini-BAL, blinded protected specimen brush, and blinded bronchial sampling) and endotracheal aspirates. J Intensive Care Med 2006, 21:17-21. 10.1177/0885066605283094, 16698740.
30. Eugen-Olsen J. suPAR: a future risk marker in bacteremia. J Intern Med 2011, 270:29-31. 10.1111/j.1365-2796.2011.02372.x, 21366732.
31. Kofoed K, Schneider UV, Scheel T, Andersen O, Eugen-Olsen J. Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology. Clin Chem 2006, 52:1284-1293. 10.1373/clinchem.2006.067595, 16690735.
32. Molkanen T, Ruotsalainen E, Thorball CW, Jarvinen A. Elevated soluble urokinase plasminogen activator receptor (suPAR) predicts mortality in Staphylococcus aureus bacteremia. Eur J Clin Microbiol Infect Dis 2011, 30:1417-1424. 10.1007/s10096-011-1236-8, 21479972.
33. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996, 93:5899-5904. 10.1073/pnas.93.12.5899, 39159, 8650190.
34. Mondino A, Blasi F. uPA and uPAR in fibrinolysis, immunity and pathology. Trends Immunol 2004, 25:450-455. 10.1016/j.it.2004.06.004, 15275645.
35. Rijneveld AW, Levi M, Florquin S, Speelman P, Carmeliet P, van Der Poll T. Urokinase receptor is necessary for adequate host defense against pneumococcal pneumonia. J Immunol 2002, 168:3507-3511.
36. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr Opin Cell Biol 2000, 12:613-620. 10.1016/S0955-0674(00)00140-X, 10978898.
37. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J Exp Med 1998, 188:1029-1037. 10.1084/jem.188.6.1029, 2212528, 9743521.
38. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 1996, 15:1572-1582. 450067, 8612581.
39. Selleri C, Montuori N, Ricci P, Visconte V, Carriero MV, Sidenius N, Serio B, Blasi F, Rotoli B, Rossi G, Ragno P. Involvement of the urokinase-type plasminogen activator receptor in hematopoietic stem cell mobilization. Blood 2005, 105:2198-2205. 10.1182/blood-2004-06-2424, 15494432.
40. Choi G, Schultz MJ, Levi M, van der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly 2006, 136:139-144.
41. Dixon B, Santamaria JD, Campbell DJ. A phase 1 trial of nebulised heparin in acute lung injury. Crit Care 2008, 12:R64. 10.1186/cc6894, 2481447, 18460218.
42. Dixon B, Schultz MJ, Smith R, Fink JB, Santamaria JD, Campbell DJ. Nebulized heparin is associated with fewer days of mechanical ventilation in critically ill patients: a randomized controlled trial. Crit Care 2010, 14:R180. 10.1186/cc9286, 3219284, 20937093.
43. Miller AC, Rivero A, Ziad S, Smith DJ, Elamin EM. Influence of nebulized unfractionated heparin and N-acetylcysteine in acute lung injury after smoke inhalation injury. J Burn Care Res 2009, 30:249-256. 10.1097/BCR.0b013e318198a268, 19165116.
44. Eugen-Olsen J, Andersen O, Linneberg A, Ladelund S, Hansen TW, Langkilde A, Petersen J, Pielak T, Møller LN, Jeppesen J, Lyngbaek S, Fenger M, Olsen MH, Hildebrandt PR, Borch-Johnsen K, Jørgensen T, Haugaard SB. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med 2010, 268:296-308. 10.1111/j.1365-2796.2010.02252.x, 20561148.